Cataract News and Research

Latest Cataract News and Research

pSivida presents data of ILUVIEN Phase 3 trial in Diabetic Macular Edema at ARVO 2011

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME Study of ILUVIEN for the treatment of Diabetic Macular Edema at the 2011 ARVO Annual Meeting.

4 May 2011

Paulig Eye Surgery Center provides non-invasive alternative to keratoconus patients

The Paulig Eye Surgery Centre announces today that it has acquired advanced technology for performing Keraflex KXL, a new, non-invasive, non-surgical treatment for keratoconus. Surgeons at the Paulig Eye Surgery Centre will immediately begin treating patients using Avedro, Inc's Keraflex and KXL Systems.

3 May 2011

STAAR Surgical receives CE Mark approval for nanoFLEX Collamer IOL lens

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced CE Mark approval for its nanoFLEX Collamer Single Piece IOL which can be injected through a 2.2 mm incision with the nanoPOINT Injector System.

28 Apr 2011

LCA-Vision reports first profitable quarter in three years

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus® brand, today announced financial and operational results for the three months ended March 31, 2011.

26 Apr 2011

STAA receives CE Mark approval for Visian Implantable Collamer Lens V4 design

STAAR Surgical Company, the leading developer, manufacturer and marketer of minimally invasive ophthalmic lenses for refractive surgery, today announced CE Mark approval for its Visian Implantable Collamer Lens V4c design.

25 Apr 2011

Surgeon presents LASIK procedure comparative study results at ASCRS Symposium

LasikPlus surgeon Dr. Lewis Groden presented results from a first-of-its-kind, comparative study at the American Society of Cataract and Refractive Surgery Symposium revealing that LASIK procedures performed with modern excimer laser technology produce excellent results and very high patient satisfaction rates.

31 Mar 2011

Carl Zeiss Meditec’s MEL 80 Excimer Laser receives PMA from FDA to treat hyperopia

Carl Zeiss Meditec, Inc. announced today that the MEL 80 Excimer Laser has received premarket approval from the U.S. Food and Drug Administration for the treatment of hyperopia.

29 Mar 2011

Abbott launches Cataract Suite for micro-implantation procedure

Abbott announced today that it has introduced a Micro-Implantation Cataract Suite designed to help improve cataract procedure outcomes and safety.

29 Mar 2011

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Genentech, a member of the Roche Group, announced today that the second of two Phase III trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint.

28 Mar 2011

Scientists develop new software to test alterations in night vision

Researchers from the Department of Optics of the University of Granada, belonging to the Laboratorio de Ciencias de la Visi-n y Aplicaciones, have developed a programme for testing alterations in night vision, and the tool required to implement it, which has been named "halometer".

25 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery.

23 Mar 2011

$FDA clears LensAR Laser System for use in refractive cataract surgery$

FDA clears LensAR Laser System for use in refractive cataract surgery

LensAR, Inc., the leading developer of next-generation laser technology for refractive cataract surgery, announced today that the company has received 510(k) clearance from the FDA for use of the LensAR™ Laser System for anterior capsulotomy and lens fragmentation during cataract surgery.

23 Mar 2011

New image resolution technology from Ellex ELX

Ellex Medical Lasers Limited (ASX:ELX), an ophthalmic laser and ultrasound technology company, today announced that it will introduce a new diagnostic ultrasound mode for its leading Eye Cubed™ system at the upcoming meeting of the American Society of Cataract and Refractive Surgeons Meeting.

22 Mar 2011

Retina Implant to join with Wills Eye for U.S. artificial vision clinical trial

Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced that they will partner with the Wills Eye Institute in Philadelphia as the lead U.S. clinical trial investigator site.

18 Mar 2011

STAA introduces phase two of its Visian ICL direct-to-consumer ad campaign

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced the launch of phase two of its direct-to-consumer advertising campaign.

17 Mar 2011

FDA approves Rochester Nomogram technology for LASIK surgery

A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.

17 Mar 2011

Omeros fourth quarter net loss increases to $7.2 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010.

15 Mar 2011

Genentech announces positive outcomes from Lucentis Phase III trial against DME

Genentech, a member of the Roche Group, today announced that two-year results from a pivotal Phase III trial showed patients with diabetic macular edema who received Lucentis experienced rapid and sustained improvement in vision compared to those who received a placebo injection.

11 Mar 2011